自身免疫性肝病重叠综合征的临床治疗探讨

冯少春; 王珊; 陈红

自身免疫性肝病重叠综合征的临床治疗探讨

1. 兰州市第二人民医院
2. 兰州大学第一临床医院

详细信息

中图分类号: R575
计量
- 文章访问数: 2296
- HTML全文浏览量: 18
- PDF下载量: 622
- 被引次数: 0
出版历程
- 出版日期: 2011-10-20

Study on the treatment of overlap syndrome of autoimmune liver disease

摘要

摘要: 目的探讨自身免疫性肝病重叠综合征的治疗方法,提高治疗的有效性与安全性。方法 32例自身免疫性肝炎（AIH）-原发性胆汁性肝硬化（PBC）重叠综合征患者,均给予强的松（0.5mg.kg-1.d-1）联合熊去氧胆酸（UDCA,15 mg.kg-1.d-1）治疗,回顾性分析治疗前、后不同时段患者疾病状态的变化,评价临床疗效。结果所有患者症状、体征明显减轻,生化指标、肝脏病理损害均明显改善,与入院前比较差异有统计学意义（P<0.01或P<0.05）。IgG、IgM、抗平滑肌抗体（SMA）、抗线粒体抗体（AMA）治疗前后无明显变化,差异无统计学意义（P>0.05）。结论强的松联合UDCA短期内能明显减轻AIH-PBC患者的临床症状、体征,改善生化学和肝组织学指标,提高患者生存质量,治疗安全有效。
- 肝炎,自身免疫性 /
- 肝硬化,胆汁性
Abstract: Objective To investigate treatment of the overlap syndrome of autoimmune liver disease and to improve the efficacy and safety of the treatment.Methods We retrospectively analyzed the clinical data of 32 cases with autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) overlap syndrome The patients were given prednisone (0.5 mg·kg-1·d-1) combined with UDCA (ursodeoxycholic acid) (15mg·kg-1·d-1) .Results The total situation of all patients improved significantly compared with pretreatment (P<0.01 or P<0.05) .The IgG, IgM, SMA, AMA level show no difference after treatment (P>0.05) .Conclusion prednisone combined UDCA treatment can significantly reduce AIH-PBC symptoms and signs of patients and improve liver biochemistry and liver histological index.The treatment is safe and effective.
- hepatitis autoimmune /
- liver cirrhosis

HTML全文

参考文献(12)

[1]贾继东.进一步提高自身免疫性肝脏疾病的诊治水平[J].中华肝脏病杂志, 2010, 18 (5) :321-322.

[2]Manns MP, Czaja AJ, Gorham JD, et al.Diagnosis andmanagement of autoimmune hepatitis[J].Hepatology, 2010, 51 (6) :2193-2213.

[3]European Association for the Study of the Liver.EASL Clini-cal Practice Guidelines:management of cholestatic liver dis-eases[J].J Hepatol, 2009, 51 (6) :1084-1085.

[4]Chazouillères O, Wendum D, Serfaty L, et al.Primary biliarycirrhosis-autoimmune hepatitis overlap syndrome:clinicalfeatures and response to therapy[J].Hepatology, 1998, 28 (2) :296-301.

[5]Mallo-González N, López-Rodríguez R, Campos-FrancoJ, et al.The autoimmune hepatitis-primary biliary cirrhosisoverlap syndrome:a case report[J].An Med Interna, 2008, 25 (3) :122-124.

[6]Czaja AJ, Freese DK.American Association for the study ofLiver Disease.Diagnosis and treatment of autoimmune hepa-titis[J].Hepatology, 2002, 36 (2) :479-497.

[7] 马雄.自身免疫性肝炎的临床诊治[J].中华肝脏病杂志, 2010, 18 (5) :324-325.

[8]陶红.原发性胆汁性肝硬化的临床诊治[J].中华肝脏病杂志, 2010, 18 (5) :326-327.

[9]Krawitt EL.Autoimmune hepatitis[J].N Engl Med, 2006, 354 (1) :54-66.

[10]Rust C, Beuers U.Overlap syndromes among autoimmune liverdiseases[J].World J Gastroenterol, 2008, 14 (21) :3368-3373.

[11]Gong Y, Huang Z, Christensen E, et al.Ursodeoxycholic acidfor patient with primary biliary cirrhosis:an updated system-atic review and meta-analysis of randomized clinical trials u-sing Bayesian approach as sensitivity analyses.Am[J].Gastroenterol, 2007, 102 (8) :1799-1807.

[12]Chazouilleres O, Wendum D, Serfaty L, et al.Long termoutcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome[J].J Hepatol, 2006, 44 (2) :400-406.

施引文献

资源附件(0)

访问统计